Alto Neuroscience (NYSE:ANRO) Trading Down 6.6% – What’s Next?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) traded down 6.6% on Wednesday . The stock traded as low as $18.38 and last traded at $17.98. 47,231 shares were traded during mid-day trading, a decline of 77% from the average session volume of 208,091 shares. The stock had previously closed at $19.26.

Analysts Set New Price Targets

ANRO has been the topic of several research analyst reports. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. BTIG Research lifted their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright increased their price objective on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Chardan Capital raised their price objective on Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average price target of $26.50.

Alto Neuroscience Stock Performance

The business’s fifty day moving average price is $16.96 and its two-hundred day moving average price is $10.94. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The stock has a market capitalization of $563.91 million, a P/E ratio of -7.93 and a beta of 2.78.

Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC lifted its stake in Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. Peapod Lane Capital LLC lifted its position in shares of Alto Neuroscience by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,106 shares during the last quarter. Torren Management LLC bought a new position in shares of Alto Neuroscience in the fourth quarter worth about $62,000. Citizens Financial Group Inc. RI lifted its holdings in Alto Neuroscience by 19.0% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after buying an additional 6,394 shares in the last quarter. Finally, AlphaCore Capital LLC grew its stake in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after acquiring an additional 10,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.